ESTRO 2024 - Abstract Book

S2002

Clinical - Mixed sites, palliation

ESTRO 2024

Results:

114 patients with 1-3 oligometastatic lesions from RPC underwent SABR between January 2017 and November 2022. Patient demographics listed in Table 2. An estimated median OS and PFS were 39 months and 14 months respectively. No grade ≥3 post RT toxicities were reported.

Table 2